Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir

References

• Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. (1982). A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother, 22:55–61.
   PubMed Web of Science ®Google Scholar
• Smee DF, Martin JC, Verheyden JP, Matthews TR. (1983). Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother, 23:676–682.
   PubMed Web of Science ®Google Scholar
• Faulds D, Heel RC. (1990). Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 39:597–638.
   PubMed Web of Science ®Google Scholar
• Mar EC, Cheng YC, Huang ES. (1983). Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother, 24:518–521.
   PubMed Web of Science ®Google Scholar
• Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU et al. (1985). Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci usa, 82:2473–2477.
   PubMed Web of Science ®Google Scholar
• Matthews T, Boehme R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis, 10 Suppl 3:S490–S494.
   PubMedGoogle Scholar
• Morse GD, Shelton MJ, O’Donnell AM. (1993). Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet, 24:101–123.
   PubMed Web of Science ®Google Scholar
• Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. (1983). Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology, 90:859–873.
   PubMed Web of Science ®Google Scholar
• Shah P, Jogani V, Mishra P, Mishra AK, Bagchi T, Misra A. (2007). Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. J Pharm Sci, 96:2710–2722.
   PubMed Web of Science ®Google Scholar
• De Mirinda P, Cederberg DM, Burnette T, Blum MR, Brodie HR, Mills, J. (1986). Absorption and pharmacokinetics of the antiviral 9-{[2-hydroxy-1-hydroxymethyl)ethoxy]methyl} guanine(BW B759U) in humans. Program and abstracts of the twenty sixth interscience conference on antimicrobial agents and chemotherapy. American society for microbiology, 200.
   Google Scholar
• Jacobson MA, de Miranda P, Cederberg DM, Burnette T, Cobb E, Brodie HR et al. (1987). Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother, 31:1251–1254.
   PubMed Web of Science ®Google Scholar
• Markham A, Faulds D. (1994). Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs, 48:455–484.
   PubMed Web of Science ®Google Scholar
• Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA et al. (1995). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med, 333:615–620.
   PubMed Web of Science ®Google Scholar
• Limaye AP. (2002). Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis, 35:866–872.
   PubMed Web of Science ®Google Scholar
• Spector SA. (1997). Current therapeutic challenges in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol, 14 Suppl 1:S32–S35.
   PubMedGoogle Scholar
• Malhotra M, Jain NK. (1994). Niosomes as drug carriers. Indian Drugs, 31:81–86.
   Google Scholar
• Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm, 26:217–222.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam A, Kumar VA, Pillai KS. (2002). Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm, 28:1181–1193.
   PubMed Web of Science ®Google Scholar
• Shaikh KS, Chellampillai B, Pawar AP. (2010). Studies on nonionic surfactant bilayer vesicles of ciclopirox olamine. Drug Dev Ind Pharm, 36:946–953.
   PubMed Web of Science ®Google Scholar
• Raja Naresh RA, Handrashekhar G, Pillai GK, Udupa N. (1994). Antiinflammatory activity of niosome encapsulated diclofenac sodium with Tween-85 in Arthitic rats. Ind J Pharmacol, 26:46–48.
   Google Scholar
• Morilla MJ, Benavidez P, Lopez MO, Bakas L, Romero EL. (2002). Development and in vitro characterisation of a benznidazole liposomal formulation. Int J Pharm, 249:89–99.
   PubMed Web of Science ®Google Scholar
• Zeisig R, Shimada K, Hirota S, Arndt D. (1996). Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. Biochim Biophys Acta, 1285:237–245.
   PubMed Web of Science ®Google Scholar
• Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. (2002). Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm, 234:237–248.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306:71–82.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Wongtrakul P, Manosroi J, Saki H, Sugawara F, Yuasa M, Abe M. (2003). Characterization of vesicles prepared with various non-ionic surfactants mixed with Cholesterol. Colloid Surf B: Biointerf, 30:129–138.
   Web of Science ®Google Scholar
• Uchegbu IF, Duncan R. (1997). Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer- doxorubicin (PK1): Effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution. Int J Pharm, 155:7–17.
   Web of Science ®Google Scholar
• Uchegbu IF, Florence AT. (1995). Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Coll Interf Sci, 58:1–55.
   Web of Science ®Google Scholar
• Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. (2002). Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci, 251:360–365.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhao F, Li N, Yang Y, Li K. (2002). Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm, 244:73–80.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Stermberg B, Florence AT. (1994). Preparation and properties of vesicles (niosomes) of sobitan monoesters (Span20, 40, 60, and 80) and a sorbitan triester (Span85). Int J Pharm, 105, 1–6.
   Web of Science ®Google Scholar
• Nagarsenker MS., Joshi AA. (1997). Preparation, characterization and evaluation of liposomal dispersions of lidocaine. Drug Dev Ind Pharm, 23:1159–1165.
   Web of Science ®Google Scholar
• Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharmscitech, 8:1.
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. (1999). Niosomal delivery of 5-fluorouracil. J Microencapsul, 16:731–740.
   PubMed Web of Science ®Google Scholar
• Cable C. (1989). An examination of the effects of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles. PhD Thesis, University of Strathclyde, Glasgow, UK.
   Google Scholar
• Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. (2005). Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm, 59:485–490.
   PubMed Web of Science ®Google Scholar
• Attia IA, El-Gizawy SA, Fouda MA, Donia AM. (2007). Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS Pharmscitech, 8:E106.
   PubMed Web of Science ®Google Scholar
• Rogerson A, Cummings J, Florence AT. (1987). Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul, 4:321–328.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Jayakar B, Ghosal SK. (2000). Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm, 26:217–222.
   PubMed Web of Science ®Google Scholar